{"Title": "ARF way to Ph 1 ALL stratification?", "Year": 2018, "Source": "Blood", "Volume": "131", "Issue": 13, "Art.No": null, "PageStart": 1394, "PageEnd": 1395, "CitedBy": 0, "DOI": "10.1182/blood-2018-02-829085", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047633413&origin=inward", "Abstract": "\u00a9 2018 by The American Society of Hematology. In this issue of Blood, Pfeifer et al have determined that CDKN2A/2B deletions are \u201ca strong and independent prognostic marker for predicting risk of relapse and overall survival\u201d when adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph 1 ALL) are treated with both imatinib and allogenic stem cell transplantation (aSCT). 1", "AuthorKeywords": null, "IndexKeywords": ["ADP-Ribosylation Factor 1", "Adult", "Genomics", "Humans", "Stem Cell Transplantation"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85047633413", "SubjectAreas": [["Biochemistry", "BIOC", "1303"], ["Immunology", "IMMU", "2403"], ["Hematology", "MEDI", "2720"], ["Cell Biology", "BIOC", "1307"]], "AuthorData": {"7102396522": {"Name": "Fielding A.", "AuthorID": "7102396522", "AffiliationID": "60109234", "AffiliationName": "UCL Cancer Institute"}}}